Pipeline J&J adds rare disease wAIHA to Imaavy’s potential uses PharmaphorumJohnson Johnson's 'Swiss army knife' drug Imaavy has shown efficacy in a pivotal trial involving patients with rare autoimmune disorder wAIHA.Rare DiseaseRead full story pharminent June 11, 2026 (Last updated: June 11, 2026) Pharmaphorum Johnson Johnson’s ‘Swiss army knife’ drug Imaavy has shown efficacy in a pivotal trial involving patients with rare autoimmune disorder wAIHA. Rare Disease Read full story Post navigation Previous: Novartis gets win for another Avidity muscular dystrophy AOCNext: Sky-high Parabilis, Kailera IPOs spur optimism–but only for derisked biotechs Related Stories Pipeline Chasing Dupixent, a biotech aims to make better antibody drugs for eczema pharminent August 11, 2026 Pipeline Epicrispr lands $90M to advance epigenetic editing drug for rare muscle disease pharminent August 11, 2026 Pipeline BioMarin axes asset from $270M Inozyme takeover, ending run in rare metabolic indication pharminent August 10, 2026
